Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Overview of attention for article published in New England Journal of Medicine, August 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 79 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 80 X users
patent: 9 patents

facebook: 5 Facebook pages
wikipedia: 3 Wikipedia pages
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 416 Mendeley

So far, Altmetric has seen 5 public wall posts from 5 users.

Binaytara Foundation, 19 Mar 2021

Dr. P Hari from the Medical College of Wisconsin is presenting on relapsed #MultipleMyeloma #mmsm , and Dr. Luciano Costa from…

Colegio Médicos Postgraduados IMSS A.C., 27 Aug 2019

Original Article from The New England Journal of Medicine — Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple…

Scientific Information & News, 26 Aug 2019

Selinexor, a drug that inhibits nuclear export of tumor suppressor proteins, was tested in a phase 2 trial involving patients…

The New England Journal of Medicine, 26 Aug 2019

Selinexor, a drug that inhibits nuclear export of tumor suppressor proteins, was tested in a phase 2 trial involving patients…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 1 additional Facebook posts.